Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

• Status: Withdrawn
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The main purpose of this study is to find out whether adding radiation therapy to the standard treatment of chemotherapy for prostate cancer is tolerated well and is more effective than the standard treatment of chemotherapy alone

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: Genzyme, a Sanofi Company
• Treatments: Docetaxel; Prednisone

Criteria

Inclusion Criteria:

• Participants must have a diagnosis of castrate resistant prostate cancer.

• Participants must be 18 years old or older.

• Biopsy of tissue from the prostate or enlarged lymph nodes may be required.

• Patients must sign study specific informed consent prior to study entry.

• Men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards.

Exclusion Criteria:

• Participants cannot have prior chemotherapy for prostate cancer.

• Participants cannot have prior radiation therapy to the pelvis.